|
MechanismIL6 gene inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评估 WBP216 在类风湿关节炎患者中的安全性、耐受性、PKPD的随机双盲、安慰剂对照、单次给药剂量递增的I期临床研究
[Translation] A randomized, double-blind, placebo-controlled, single-dose escalation phase I clinical study to evaluate the safety, tolerability, and PKPD of WBP216 in patients with rheumatoid arthritis
评估WBP216单剂量以及多剂量递增对RA患者的安全性、耐受性、药代动力学和药效学。
[Translation] To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose and multiple-ascending doses of WBP216 in RA patients.
评估WBP216多次皮下注射在类风湿关节炎患者中的药代动力学、药效学、安全性、耐受性及初步有效性的Ib期临床研究
[Translation] Phase Ib clinical study to evaluate the pharmacokinetics, pharmacodynamics, safety, tolerability and preliminary efficacy of WBP216 after multiple subcutaneous injections in patients with rheumatoid arthritis
评价不同剂量的WBP216多次给药在类风湿关节炎(RA)患者中的PK和PD特征,并评估多次给药后的安全性和耐受性,初步探索WBP216在RA患者中的有效性,为后续II、III 期临床试验给药方案(包括给药剂量和给药周期)的确定提供科学依据。
[Translation] To evaluate the PK and PD characteristics of multiple administrations of different doses of WBP216 in patients with rheumatoid arthritis (RA), and to assess the safety and tolerability after multiple administrations, to preliminarily explore the effectiveness of WBP216 in RA patients, and to provide a scientific basis for determining the dosing regimen (including dosage and dosing cycle) for subsequent Phase II and III clinical trials.
100 Clinical Results associated with WuXi MedImmune Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with WuXi MedImmune Biopharmaceutical Co., Ltd.
100 Deals associated with WuXi MedImmune Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with WuXi MedImmune Biopharmaceutical Co., Ltd.